Fracture prevention in patients with cognitive impairment presenting with a hip fracture: Secondary analysis of data from the HORIZON Recurrent Fracture Trial

Osteoporosis International

Volumn 25, Issue 1, 2014, Pages 77-83

  Prieto Alhambra, D ^a,b,c,d,e,f   Judge, A ^a,f   Arden, N K ^a,f   Cooper, C ^a,b,f   Lyles, K W ^g,h   Javaid, M K ^a,f,i  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUT CATALÀ DE LA SALUT   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g DUKE UNIVERSITY   (United States)

^h Carolinas Center for Medical Excellence   (United States)

ⁱ NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

Bone; Dementia; Epidemiology; Fractures; Mortality; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SHORT PORTABLE MENTAL STATUS QUESTIONNAIRE; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COGNITION DISORDERS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; IMIDAZOLES; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TREATMENT OUTCOME;

EID: 84891856389     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2420-8     Document Type: Article

References (33)

1. Ström O, Borgström F, Kanis J, Compston J, Cooper C, McCloskey E, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6(1-2):59-155
2. Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JE, Wahl DA (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051-2065
3. Lloyd BD, Williamson DA, Singh NA, Hansen RD, Diamond TH, Finnegan TP, Allen BJ, Grady JN, Stavrinos TM, Smith EU, Diwan AD, Fiatarone Singh MA (2009) Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study. J Gerontol A Biol Sci Med Sci 64:599-609
4. Beringer TR, Clarke J, Elliott JR, Marsh DR, Heyburn G, Steele IC (2006) Outcome following proximal femoral fracture in Northern Ireland. Ulster Med J 75:200-206 (Pubitemid 44321306)
5. Curtis JR, Arora T, Matthews RS, Taylor A, Becker DJ, Colon-Emeric C, Kilgore ML, Morrisey MA, Saag KG, Safford MM, Warriner A, Delzell E (2010) Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 11:584-591
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
7. Vik SA, Jantzi M, Poss J, Hirdes J, Hanley DA, Hogan DB, Maxwell CJ (2007) Factors associated with pharmacologic treatment of osteoporosis in an older home care population. J Gerontol A Biol Sci Med Sci 62:872-878 (Pubitemid 350131672)
8. Haasum Y, Fastbom J, Fratiglioni L, Johnell K (2012) Undertreatment of osteoporosis in persons with dementia? A population-based study. Osteoporos Int 23:1061-1068
9. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809 (Pubitemid 350044800)
10. Pfeiffer E (1975) A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23:433-441
11. Erkinjuntti T, Sulkava R, Wikstrom J, Autio L (1987) Short Portable Mental Status Questionnaire as a screening test for dementia and delirium among the elderly. J Am Geriatr Soc 35:412-416 (Pubitemid 17070606)
12. Berry SD, Ngo L, Samelson EJ, Kiel DP (2010) Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 58:783-787
13. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistributions of a competing risk. J Am Stat Assoc 94:496-509
14. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219 (Pubitemid 36143396)
15. Sun X, Briel M, Walter SD, Guyatt GH (2010) Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 340:c117
16. Leslie WD, Lix LM, Wu X (2012) Competing mortality and fracture risk assessment. Osteoporos Int 24:681-688
17. Tinetti ME, Kumar C (2010) The patient who falls: "It's always a trade-off". JAMA 303:258-266
18. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
19. Ensberg MD, Paletta MJ, Galecki AT, Dacko CL, Fries BE (1993) Identifying elderly patients for early discharge after hospitalization for hip fracture. J Gerontol 48:M187-195
20. Heruti RJ, Lusky A, Barell V, Ohry A, Adunsky A (1999) Cognitive status at admission: does it affect the rehabilitation outcome of elderly patients with hip fracture? Arch Phys Med Rehabil 80:432-436 (Pubitemid 29171958)
21. Cree M, Carriere KC, Soskolne CL, Suarez-Almazor M (2001) Functional dependence after hip fracture. Am J Phys Med Rehabil 80:736-743 (Pubitemid 32888738)
22. Hirose J, Ide J, Yakushiji T, Abe Y, Nishida K, Maeda S, Anraku Y, Usuku K, Mizuta H (2010) Prediction of postoperative ambulatory status 1 year after hip fracture surgery. Arch Phys Med Rehabil 91:67-72
23. Ceder L, Elmqvist D, Svensson SE (1981) Cardiovascular and neurological function in elderly patients sustaining a fracture of the neck of the femur. J Bone Joint Surg Br 63B:560-566 (Pubitemid 11029174)
24. Wood DJ, Ions GK, Quinby JM, Gale DW, Stevens J (1992) Factors which influence mortality after subcapital hip fracture. J Bone Joint Surg Br 74:199-202
25. Evans JG, Prudham D, Wandless I (1979) A prospective study of fractured proximal femur: factors predisposing to survival. Age Ageing 8:246-250 (Pubitemid 10161177)
26. Maxwell MJ, Moran CG, Moppett IK (2008) Development and validation of a preoperative scoring system to predict 30 day mortality in patients undergoing hip fracture surgery. Br J Anaesth 101:511-517
27. Wiles MD, Moran CG, Sahota O, Moppett IK (2011) Nottingham Hip Fracture Score as a predictor of one year mortality in patients undergoing surgical repair of fractured neck of femur. Br J Anaesth 106(4):501-504
28. Currie C, Partridge M, Plant F, Roberts J, Wakeman R, Williams A (2011) The National Hip Fracture Database National Report 2011. In Partnership HQI (ed).
29. Sato Y, Kanoko T, Satoh K, Iwamoto J (2005) The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 165:1737-1742 (Pubitemid 41138961)
30. Halbekath JM, Schenk S, von Maxen A, Meyer G, Muhlhauser I (2007) Risedronate for the prevention of hip fractures: concern about validity of trials. Arch Intern Med 167:513-514, author reply 514-515 (Pubitemid 46425670)
31. Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91-97
32. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, Bala MM, Bassler D, Mertz D, Diaz-Granados N, Vandvik PO, Malaga G, Srinathan SK, Dahm P, Johnston BC, Alonso-Coello P, Hassouneh B, Walter SD, Heels-Ansdell D, Bhatnagar N, Altman DG, Guyatt GH (2012) Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ 344:e1553
33. Oxman AD (2012) Subgroup analyses. BMJ 344:e2022